Sponsors (51)
The bill substantially expands no‑cost HIV prevention access, privacy protections, and outreach—improving prevention and equity for many Americans—while increasing federal/state spending, administrative burdens, and litigation/privacy risks that could raise costs or complicate implementation.
People at risk of HIV across public and private coverage (private group/individual plans, Medicare, Medicaid/CHIP, VA, TRICARE, veterans, and uninsured reachable via grant programs) will get FDA‑approved HIV prevention drugs, related labs, and follow‑up with no cost‑sharing (deductibles/copays waived, Part D cost‑sharing eliminated for certain years), lowering out‑of‑pocket costs and financial Bar
People taking HIV‑prevention medication (PrEP/PEP) cannot be denied or charged higher rates for life, disability, or long‑term care insurance, preserving access to other insurance products and reducing insurance‑based stigma or discrimination.
Individuals covered on family health plans can obtain confidential preventive services (permitted to receive certain services without other enrollees being notified), protecting privacy for sensitive care and likely increasing uptake of STI screening, contraceptive care, and other recommended services.
Federal and state governments (and ultimately taxpayers and some enrollees) will face higher spending to cover no‑cost preventive HIV drugs and services and to fund outreach programs; high drug prices could magnify fiscal pressure and may translate into higher premiums or taxes over time.
Insurers, self‑funded plans, states, providers, and administrators will incur significant administrative and compliance costs (annual reporting for years, system modifications to segregate confidential claims, training and grant compliance) that may be passed to consumers or strain small practices and state budgets.
The law creates or invites more private litigation (private right of action plus ambiguous underwriting language), increasing liability exposure and litigation costs for defendants (including small businesses and nonprofits) and adding workload to courts.
Based on analysis of 20 sections of legislative text.
Requires private plans to cover FDA‑approved PrEP/PEP and related services without cost‑sharing or broad prior authorization, adds privacy and nondiscrimination rules, and creates grants and education to expand access.
Official title: To increase access to pre-exposure prophylaxis to reduce the transmission of HIV.
Introduced March 5, 2026 by Mark Takano · Last progress March 5, 2026
Requires private group and individual health plans to cover FDA‑approved HIV prevention drugs (PrEP and PEP) and associated services without cost‑sharing and largely without prior authorization, strengthens privacy for people using those services, forbids life/disability/long‑term care insurers from discriminating based on preventive HIV drug use, and creates federal grants and public/provider education campaigns to expand access. It also requires plan reporting, federal monitoring and public reporting on compliance, and creates a private right of action allowing enforcement by individuals or classes.